Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Chronic Migraine in Korea

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01976611

Enrollment

402

Registered

2013-11-06

Start date

2012-06-30

Completion date

2015-02-28

Last updated

2015-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Headache, Migraine Disorders

Brief summary

This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of botulinum toxin Type A to treat Chronic Migraine in clinical practice.

Interventions

BIOLOGICALbotulinum toxin Type A

Botulinum toxin Type A treatment for chronic migraine as per local standard of care in clinical practice.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients treated with botulinum toxin Type A for chronic migraine in clinical practice.

Exclusion criteria

* None.

Design outcomes

Primary

Measure	Time frame
Number of Participants with Adverse Events and Adverse Drug Reactions	4 Years
Headache Impact Test-6 (HIT-6) Score Using a 5-Point Scale	4 Years

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026